NASDAQ:CSTL

Castle Biosciences Stock Forecast, Price & News

$75.79

-3.38 (-4.27 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$74.74

Now: $75.79▼

$81.18

50-Day Range

$54.19

MA: $70.12▼

$81.48

52-Week Range

$21.01

Now: $75.79▼

$84.00

Volume265,487 shs

Average Volume240,213 shs

Market Capitalization$1.53 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.46

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Overall MarketRank^™

1.51 out of 5 stars

Medical Sector

420th out of 1,922 stocks

Medical Laboratories Industry

5th out of 39 stocks

1.5 Analyst's Opinion

Consensus Rating
Castle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.00, Castle Biosciences has a forecasted downside of 9.0% from its current price of $75.79.
Amount of Analyst Coverage
Castle Biosciences has only been the subject of 4 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Castle Biosciences has received 59 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Castle Biosciences has received 42 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Castle Biosciences has received 58.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Castle Biosciences and other stocks. Vote “Outperform” if you believe CSTL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CSTL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Castle Biosciences does not currently pay a dividend.
Dividend Growth
Castle Biosciences does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,084,561.00 in company stock.
Percentage Held by Insiders
39.70% of the stock of Castle Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.42% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Castle Biosciences are expected to grow in the coming year, from ($0.40) to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Castle Biosciences is -445.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Castle Biosciences is -445.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Castle Biosciences has a P/B Ratio of 15.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CSTL

Previous Symbol

CUSIPN/A

CIKN/A

Webcastlebiosciences.com

Phone866-788-9007

Employees133

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.07

Current Ratio6.65

Quick Ratio6.59

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$51.87 million

Price / Sales29.45

Cash Flow$0.14 per share

Price / Cash Flow539.36

Book Value$4.98 per share

Price / Book15.22

Profitability

EPS (Most Recent Fiscal Year)($0.81)

Net Income$5.28 million

Net Margins-5.30%

Return on Equity-2.69%

Return on Assets-2.05%

Miscellaneous

Outstanding Shares20,156,000

Market Cap$1.53 billion

Next Earnings Date3/9/2021 (Estimated)

OptionableNot Optionable

$75.79

-3.38 (-4.27 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CSTL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.

Castle Biosciences (NASDAQ:CSTL) Frequently Asked Questions

How has Castle Biosciences' stock been impacted by Coronavirus?

Castle Biosciences' stock was trading at $28.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CSTL shares have increased by 161.6% and is now trading at $75.79.
View which stocks have been most impacted by COVID-19.

Is Castle Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Castle Biosciences stock.
View analyst ratings for Castle Biosciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Castle Biosciences?

Wall Street analysts have given Castle Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Castle Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Castle Biosciences' next earnings date?

Castle Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Castle Biosciences.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings data on Saturday, November, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.12. The company had revenue of $15.22 million for the quarter, compared to analysts' expectations of $15.31 million. Castle Biosciences had a negative trailing twelve-month return on equity of 2.69% and a negative net margin of 5.30%.
View Castle Biosciences' earnings history.

What price target have analysts set for CSTL?

5 brokerages have issued 1-year price targets for Castle Biosciences' shares. Their forecasts range from $35.00 to $80.00. On average, they anticipate Castle Biosciences' share price to reach $69.00 in the next twelve months. This suggests that the stock has a possible downside of 9.0%.
View analysts' price targets for Castle Biosciences or view Wall Street analyst' top-rated stocks.

Who are some of Castle Biosciences' key competitors?

Some companies that are related to Castle Biosciences include Elekta AB (publ) (EKTAY), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), Genetron (GTH), Personalis (PSNL), Fulgent Genetics (FLGT), Renalytix AI (RNLX), RadNet (RDNT), DermTech (DMTK), Progenity (PROG), Centogene (CNTG), Exagen (XGN), Enzo Biochem (ENZ) and Celcuity (CELC).
View all of CSTL's competitors.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Square (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

Who are Castle Biosciences' key executives?

Castle Biosciences' management team includes the following people:

Mr. Derek J. Maetzold, Founder, CEO, Pres & Director (Age 58, Pay $1.14M)
Mr. Frank Stokes, Chief Financial Officer (Age 50, Pay $529.34k)
Ms. Kristen Oelschlager R.N., RN, Chief Operations Officer (Age 52)
Ms. Alice Bahner Izzo, VP of Marketing
Mr. Toby W. Juvenal, Chief Commercial Officer (Age 60)
Dr. Robert W. Cook, Sr. VP of R&D (Age 48)
Mr. Bernhard E. Spiess, Chief Bus. Officer (Age 60)

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Creative Financial Designs Inc. ADV (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Castle Biosciences stock include Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Frank Stokes, Joseph C Cook III, Mara G Aspinall, Mgc Venture Partners 2013 Gp, and Sofinnova Healthquest Partners.
View institutional ownership trends for Castle Biosciences.

Which major investors are buying Castle Biosciences stock?

CSTL stock was purchased by a variety of institutional investors in the last quarter, including Creative Financial Designs Inc. ADV, and Nisa Investment Advisors LLC. Company insiders that have bought Castle Biosciences stock in the last two years include David S Kabakoff, and Mgc Venture Partners 2013 Gp,.
View insider buying and selling activity for Castle Biosciences or or view top insider-buying stocks.

How do I buy shares of Castle Biosciences?

Shares of CSTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $75.79.

How big of a company is Castle Biosciences?

Castle Biosciences has a market capitalization of $1.53 billion and generates $51.87 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.81) on an earnings per share basis. Castle Biosciences employs 133 workers across the globe.

What is Castle Biosciences' official website?

The official website for Castle Biosciences is castlebiosciences.com.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company can be reached via phone at 866-788-9007 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here